To Assess and Compare the Efficacy of Cyclosporine Versus Azathioprine in the Treatment of Chronic Refractory Urticaria

Chronic Refractory Urticaria Clinical Trial

Official title:

A Randomised Study to Assess and Compare the Efficacy of Cyclosporine Versus Azathioprine in the Treatment of Chronic Refractory Urticaria

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03250143
• Other study ID #: INT/IEC/2017/609
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: May 19, 2017
• Last updated: January 10, 2018
• Start date: December 6, 2016
• Est. completion date: November 2017

Study information

• Verified date: January 2018
• Source: Postgraduate Institute of Medical Education and Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Fifty six patients of CRU attending the urticaria clinic in the department of Dermatology, Venereology and Leprology at the Post Graduate Institute of Medical Education and Research, Chandigarh will be recruited in the study calculated by using equivalence analysis assuming power of 90%, significance level of 5% and standard deviation of 1 and adjusting 5% of expected drop-outs after taking written informed consent. This study is undertaken with an intention to treat the patients of chronic refractory urticaria completely. Patients will be randomized into two groups A and B using computer generated random number tables, group A will receive Cyclosporine and group B will receive Azathioprine; wherein, 28 random single and double-digit numbers from 1-56 will be selected before recruitment, and patients coming on these numbers will be randomized in a particular group. Random number generation, recruitment and randomization, were all done by the same investigator..

Description:

Available definition for chronic refractory urticaria (CRU) is chronic spontaneous urticaria, with disease duration of at least 6 months or above, which is not controlled with four fold increased dosage of antihistamines (as per EAACI guidelines), given for at least three consecutive months and requiring repeated courses of oral corticosteroids. There is no strict number of oral corticosteroids intake courses before the patient can be labeled as chronic refractory urticaria.

Study end- points

1. Primary end-point :

Change in urticaria activity score (UAS7) i.e decrease more than 75% from baseline to week 12 (at end of treatment) within group A and B and comparison between corresponding groups.

2. Secondary end-points :

1. Change in outcome scoring scale (OSS) from baseline to week 12 within group A and B.

2. Change in UAS7 and OSS from baseline to week 24 (end of follow-up) within group A and B.

3. Change in ASST, APST, IgE levels from baseline to week 12 within group A and B.

4. Comparison for the above mentioned parameters between group A and B. Treatment sessions will be for three months, daily oral cyclosporine and daily oral azathioprine and after completion, patients will be additionally followed for three more months.

Oral cyclosporine 3mg/kg/day (200mg/day) will be started and given for one week, if patient shows improvement, the same dose will be continued for the total study period ( three months) ,after physical examination and various laboratory testing most importantly renal function tests, blood pressure monitoring, hemogram and if no symptomatic improvement then dose of cyclosporine will be increased slowly till 5 mg/kg /day.

Oral azathioprine will be started at 1mg/kg/day ( 50mg/day) for one week , if patient demonstrates improvement, same dose is continued for the total study period ( 3months), after physical examination and various laboratory testing i.e LFTs, Hemogram, if no symptomatic improvement then dose of azathioprine will be increased to 2mg/kg/day (100mg/day).

All the patients will be uniformly started on levocetrizine 10mg/day, which will continue daily for one month in all patients followed by stopping the drug and adding only if the patient is symptomatic.

After three months both the drugs will be stopped and levocetrizine (10mg/day) will be continued for three months of follow up period.

Clinical assessment of patients will be done before the starting of cyclosporine and azathioprine, and every fortnightly during three months of treatment and during three months of follow up period. Assessment will be done using UAS7and OSS as devised by Berroeta et al.

URTICARIA ACTIVITY SCORE Table-2 SCORE WEALS PRURITUS

0 None None

1 Mild (<20 weals / 24 hours) Mild (present but not troublesome)

2 Moderate (20-50 weals / 24 hours) Moderate (troublesome but does not interfere with sleep)

3 Severe (>50 weals / 24 hours) Severe (sufficiently troublesome to interfere with normal daily activity and sleep)

Scores of both parameters i.e. number of weals and severity of the pruritus per day are to be added to get UAS of that day and average UAS over 7 days is calculated which will range between 0 to 6. Patients will be instructed to write down number of weals and severity of itching in their daily urticaria diary. UAS7 will be calculated every fortnightly by calculating average of weal and itch score of the previous seven days after taking detailed history from patient.

UAS7 SCORES71 HEALTH STATE

0 Urticaria free

1-6 Well controlled urticaria

7-15 Mild urticaria

16-27 Moderate urticaria

26-42 Severe urticaria

OUTCOME SCORING SCALE Another assessment scale i.e.Outcome scoring scale devised by Berroeta et al 22 for cyclosporine and azathioprine treatment of CU will also be used for clinical assessment of subjects.

1- No change 2 - Minimal improvement (no change in frequency or extent, symptomatic improvement ±) 3- Moderate improvement (less frequent or extensive, symptomatic improvement +) 4- Marked improvement (occasional episodes and less extensive, symptomatic improvement ++) 5- Clearance

In addition, ASST , APST and IgE levels will be done before starting cyclosporine and azathioprine and at the completion of the treatment after three months.

FOLLOW UP After completion of oral cyclosporine and oral azathioprine for three months, patients will be followed up for a period of three more months, every fortnightly in urticaria clinic. At each visit, clinical assessment will be done using UAS7 and OSS. Urticaria being a type 1 hypersensitivity reaction, will relapse immediately as soon as the treatment is withheld. So, a follow up period of three months will be sufficient enough to study the effect of cyclosporine and azathioprine on long term remission of urticaria. Patients developing angioedema and having uncontrolled excessive exacerbation during treatment will be removed from study and will be treated accordingly.

Patients who will fail to take the treatment for ≥ one week will be defined as defaulters and removed from the study. Those with no improvement even after one month of regular treatment will be labelled as non responders.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: November 2017
• Est. primary completion date: November 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Available definition for chronic refractory urticaria (CRU) is chronic spontaneous urticaria, with disease duration of at least 6 months or above, which is not controlled with four fold increased dosage of antihistamines (as per EAACI guidelines) figure1, given for at least three consecutive months and requiring repeated courses of oral corticosteroids.

Age = 18 years.

Exclusion Criteria:

• Patients giving history of fainting, bronchospasm during previous attacks of urticaria that is suggestive of anaphylaxis.

• Urticaria< 6 weeks.

• Age <18 years.

• Physical and pressure urticaria.

• Urticarial vasculitits.

• Pregnant and lactating patients.

• Cataract, hepatic or renal diseases, severe infections, poorly controlled hypertension

• Concomitant intake of drugs like nephrotoxic drugs (gentamycin, vancomycin, amphotericin-B, indomethacin, diclofenac, H2 antihistamines like ranitidine, cimetidine, phenobarbitone, rifampicin, allupurinol, febuxostat).

• History suggestive of allergy to azathioprine , cyclosporine.

• Absolute contraindications69 of azathioprine are severe infections, severly impaired hepatic or bone marrow function, pancreatitis, live vaccines, pregnancy and lactation.

• Patients with chronic kidney disease, uncontrolled hypertension, renal insufficiency, uncontrolled infections, cutaneous T-cell lymphoma, including mycosis fungoides, should not be given Cyclosporine70.

• Patients who are planning pregnancy.

Related Conditions & MeSH terms

• Chronic Refractory Urticaria
• Urticaria

Intervention

Drug:
• cyclosporine vs azathioprine
Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day

Locations

Country	Name	City	State
India	PGIMER	Chandigarh

Sponsors (1)

Lead Sponsor	Collaborator
Postgraduate Institute of Medical Education and Research

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in UAS7(urticaria activity score) ranging between( numerical value) 0-6 average of 7 days( primary end point)	Change in urticaria activity score (UAS7) ranging between 0-6 in average of 7 days i.e decrease more than 75% from baseline to week 12 (at end of treatment) within group A and B and comparison between corresponding groups.	12 weeks
Secondary	Change in OSS(outcome scoring scale) from baseline to 12 weeks ranging between( numerical value) 0-5 ( secondary end point)	a. Change in outcome scoring scale (OSS) ranging between 0-5 from baseline to week 12 within group A and B.	12 weeks
Secondary	Change in ASST, APST( in milimeters),( numerical value) from baseline to week 12 within group A and B	Change in autologous serum and plasma skin tests measured in milimeters and considering its positivity and negativity within group A and B.	12 weeks
Secondary	Change in S.IgE levels ( in UI/ml) from baseline to week 12 within group A and B	Change in serum IgE levels (in UI/ml) noted at baseline to week 12 within group A and B.	12 weeks
Secondary	Change in both UAS7 and OSS ( secondary end point.	Change in UAS7 and OSS from baseline to week 24 (end of follow-up) within group A and B.	24 weeks